Story March 20 - Elevation Oncology: The biotech is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data and laying off 70% of its staff as a result. The restructuring ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

On Crowncast, Enrico Pesenti explains how cancer drug resistance forms and how advanced technologies are helping researchers ...

Mural Oncology is a biotechnology company that focuses on using its protein engineering platform to develop cytokine-based immunotherapies for cancer treatment. The company aims to deliver ...

Immuno-oncology expert Gera Goverse explains how combination therapies and innovative CAR-T strategies are reshaping the cancer treatment landscape.

The approach is an ultrasound-based technique that offers a pain-free alternative. Singapore’s oncology field is set for a ...

SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage ... Abid brings over 20 years of experience in the biotechnology sector with expertise in financial strategy ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff Oncology, Inc. (NASDAQ:CRDF) stands against other hot biotech stocks ...

Mural Oncology will halt nemvaleukin’s development for ovarian cancer but continues its evaluation in mucosal and cutaneous melanoma trials. The ‘Trade of the Day’ is now live. Get a high ...